Overexpression of HSP27 and HSP70 is associated with decreased survival among patients with esophageal adenocarcinoma

Table 1 Patient and cancer characteristics

Characteristics	n (%)
mean age	64.7 yr (range 38–92 yr)1
Male sex	80%1
Stage
Stage I–IIA	11 (11.8)
Stage IIB–III	56 (60.2)
Stage IVA–IVB	21 (22.6)
Unknown	5 (5.4)
Grade
Grade I	11 (11.8 )
Grade II	32 (34.4 )
Grade III	44 (47.3)
Unknown	6 (6.5 )
Radical surgery	38 (40.9)
Definitive oncological treatment	5 (5.4)
Palliative treatment	50 (53.7)
Cause of death2
Esophageal carcinoma	59 (85.5)
Myocardial infarction	2 (2.9)
Pneumonia	2 (2.9)
Other type of carcinoma	1 (1.4)
Pulmonary embolism	1 (1.4)
Cerebral infarction	1 (1.4)
Unknown	2 (2.9)

¹80 patients with data available.

²69 patients died during follow-up.

Table 2 Frequencies of heat shock protein 27 immunostaining n (%)

HSP27	Stage I - IIA	Stage IIB - III	Stage IVA - IVB	Unknown stage
Low	4 (40)	25 (47.1)	5 (23.8)	2 (40)
High	6 (60)	28 (52.8)	16 (76.2)	3 (60)
No. of cases	10	53	21	5
HSP27	Normal	BE	BE + LGD	BE + HGD
Low	3 (50)	1 (50)	1 (50)	3 (33.3)
High	2 (50)	1 (50)	1 (50)	6 (66.7)
No. of cases	5	2	2	9

BE: Barrett’s esophagus; LGD: Low grade dysplasia HGD: High grade dysplasia.

Table 3 Frequencies of heat shock protein 70 immunostaining n (%)

HSP70	Stage I - IIA	Stage IIB - III	Stage IVA - IVB	Unknown stage
Low	9 (81.8)	40 (71.4)	12 (57.1)	4 (80)
High	2 (18.2)	16 (28.6)	9 (42.9)	1 (20)
No. of cases	11	56	21	5
HSP70	Normal	BE	BE + LGD	BE + HGD
Low	5 (100)	1 (50)	2 (100)	2 (22.2)
High	0	1 (50)	0	7 (77.8)
No. of cases	5	2	2	9

BE: Barrett’s esophagus; LGD: Low grade dysplasia HGD: High grade dysplasia.

Table 4 Overall survival and (number of patients at risk) at 6, 12 and 36 mo

	mean survival	OS 6 mo	OS 1 yr	OS 3 yr
HSP27 (72)
Low (23)	49	91.3% (21)	60.9% (14)	39.1% (9)
High (49)	23	69.4% (34)	44.9% (22)	16.3% (8)
HSP70 (76)
Low (49)	40	87.8% (43)	61.2% (30)	30.6% (15)
High (27)	17	59.3% (16)	33.3% (9)	11.1% (3)

OS: Overall survival.